^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Q-1802

i
Other names: Q-1802
Company:
Viva Biotech
Drug class:
PD-L1 inhibitor, CLDN18.2 inhibitor
Related drugs:
7ms
Development and validation of ELISA method for quantification of Q-1802 in serum and its application to pharmacokinetic study in ICR Mouse. (PubMed, J Pharm Biomed Anal)
In conclusion, we have developed and validated a highly sensitive and selective method for measuring Q-1802 in ICR mouse serum. The development and validation steps of assays met the required criteria for validation, which suggested that these can be applied to quantify Q-1802, as well as in PK studies.
PK/PD data • Preclinical • Journal
|
CLDN18 (Claudin 18)
|
Q-1802
over1year
New P1/2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
|
HER-2 negative
|
capecitabine • oxaliplatin • Q-1802
over1year
A Study of Q-1802 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=66, Recruiting, QureBio Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Jan 2023 --> Jul 2024 | Trial primary completion date: Aug 2022 --> Apr 2024
Enrollment open • Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
Q-1802
almost2years
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors. (ASCO-GI 2023)
Interim data from the present phase 1 study, demonstrate that Q-1802 has excellent preliminary safety, tolerability and preliminary anti-tumor activity up to doses of 20 mg/kg. The dose extension is still ongoing. Clinical trial information: NCT04856150.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18)
|
CLDN18.2 expression • CLDN18.2 positive
|
Q-1802
over2years
Safety results of Q-1802, a Claudin18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study. (ASCO 2022)
Q-1802 bsABs has presented safe and well-tolerated profile up to doses of 10 mg/kg. The dose escalation is still in progress.
Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CLDN18 (Claudin 18) • CLDN8 (Claudin 8)
|
CLDN18.2 expression
|
Q-1802
over3years
Clinical • New P1 trial
|
PD-L1 (Programmed death ligand 1)
|
Q-1802